口服大麻素类药物缓解晚期癌症姑息治疗患者症状负担:1:1 THC/CBD 双盲安慰剂对照随机临床试验
主要目标是评估递增剂量对总症状评分变化的影响,次要目标包括患者自定有效剂量、身体与情绪症状评分、总体变化印象、焦虑抑郁、阿片类药物使用、生活质量及不良反应。
要点
- 口服1:1 THC/CBD滴定剂量对比安慰剂,评估晚期癌症姑息治疗症状负担改善。
- 主要终点为总症状评分变化,次要终点涵盖患者自定有效剂量、情绪症状及阿片使用等。
- 采用2周患者自定滴定期加2周稳定剂量评估期的设计,剂量范围2.5/2.5至30/30 mg/日。
核心结论
- 该试验旨在明确1:1 THC/CBD制剂在晚期癌症标准姑息治疗患者症状管理中的作用,尚待结果报告。
研究设计与样本
- 受试者随机分配至口服1:1 THC/CBD制剂递增剂量组或安慰剂组。
- 干预包括2周患者自定滴定期以达到症状缓解且副作用可耐受的剂量,随后2周稳定剂量评估期。
关键数值与推荐
- 口服溶液规格为10 mg/10 mg/mL,剂量范围2.5 mg/2.5 mg至30 mg/30 mg/日。
- 主要目标为评估递增剂量1:1 THC/CBD对比安慰剂对总症状评分变化的影响。
- 次要目标包括患者自定有效剂量、身体与情绪症状评分变化、总体变化印象、焦虑抑郁、阿片使用、生活质量及不良反应。
临床怎么用
- 该研究结果将为临床医生向希望使用大麻类产品缓解晚期恶性肿瘤症状的患者提供证据参考。
局限性
- 原文未报告研究结果,无法评估疗效与安全性结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite improvements in medical care, patients with advanced cancer still experience substantial symptom distress. There is increasing interest in the use of medicinal cannabinoids but little high-quality evidence to guide clinicians. This study aims to define the role of a 1:1 delta-9-tetrahydrocannabinol/cannabidiol (THC/CBD) cannabinoid preparation in the management of symptom burden in patients with advanced cancer undergoing standard palliative care. METHODS AND DESIGN: One hundred fifty participants will be recruited from five sites within the Queensland Palliative Care Research Group (QPCRG) and randomly assigned to an active treatment or placebo group. This study is a pragmatic multicentre, randomised, placebo-controlled, two-arm trial of escalating doses of an oral 1:1 THC/CBD cannabinoid preparation. It will compare efficacy and safety outcomes of a titrated dose (10 mg/10 mg/mL oral solution formulation, dose range 2.5 mg/2.5 mg-30 mg/30 mg/day) against placebo. There is a 2-week patient-determined titration phase, using escalating doses of 1:1 THC/CBD or placebo, to reach a dose that achieves symptom relief with tolerable side effects. This is then followed by a further 2-week assessment period on the stable dose determined in collaboration with clinicians. The primary objective is to assess the effect of escalating doses of a 1:1 THC/CBD cannabinoid preparation against placebo on change in total symptom score, with secondary objectives including establishing a patient-determined effective dose, the change in total physical and emotional sores, global impression of change, anxiety and depression, opioid use, quality of life and adverse effects. DISCUSSION: This will be the first placebo-controlled clinical trial to rigorously evaluate the efficacy, safety and acceptability of 1:1 THC/CBD for symptom relief in advanced cancer patients. This study will allow the medical community to have some evidence to present to patients wishing to access cannabis for their symptoms caused by advanced malignancy. TRIAL REGISTRATION: ACTRN, ACTRN12619000037101 . Registered on 14 January 2019. Trial Sponsor: Mater Misericordiae Limited (MML) and Mater Medical Research Institute Limited (MMRI)-Raymond Terrace, South Brisbane, Brisbane, QLD, Australia.
引用
- Hardy J, Haywood A, Gogna G, et al. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Trials. 2020. PMID: 32631447. doi:10.1186/s13063-020-04541-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。